Lay-Harn Gam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Lay-Harn Gam has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Manjit Singh
Department of Surgery, Penang General Hospital, Penang, Malaysia
6 shared publicationsBoon-Hui Gooi
Surgery Department, Penang General Hospital, Penang, Malaysia
3 shared publicationsRana Khudhair Jasim
3 shared publicationsXuan-Yi Sim
School of Pharmaceutical Sciences, Universiti Sains Malaysia, 11800 Minden, Penang, MALAYSIA; USM-RIKEN Centre for Aging Science (URICAS), Universiti Sains Malaysia, 11800 Minden, Penang, MALAYSIA
3 shared publicationsZhari Ismail
School of Pharmaceutical Sciences, Universiti Sains Malaysia, USM, 11800, Penang, Malaysia
3 shared publicationsAishah Latiff
2 shared publications
Latest Publications
- 24 June 2025
- Published by Elsevier in Behavioural Brain Research
- Vol. 493, 115709
Comparative brain proteome analysis of an Indole Alkaloid of Kratom, Mitragynine and Kratom juice in rats
- 24 June 2025
- Published by Elsevier in Behavioural Brain Research
- Vol. 493, 115709
Comparative brain proteome analysis of an Indole Alkaloid of Kratom, Mitragynine and Kratom juice in rats
- Open Access
- 25 December 2024
- Published by Persatuan Biologi Gunaan Malaysia in Malaysian Applied Biology
- Vol. 53 (6) , 49-57
Changes of Pancreatic Protein Profile Upon High Fat Diet Intake In Diabetic Rat Model
The impact of a high-fat diet (HFD) on changes in pancreatic protein expression of the T2DM rat model was investigated. This is important as proteins are the functional components that regulate an organ’s activity. Adult male Sprague-Dawley rats were induced to diabetes using streptozotocin (STZ) and nicotinamide (NA). The diabetic rats and control rats were respectively fed with either a normal diet (ND) or a high-fat diet (HFD) that contained 39% fat for 6 consecutive weeks. The pancreases were harvested from the rats for proteomic analysis upon completion of the treatment period. Two-dimensional electrophoresis (2-DE) analysis was applied for protein separation and the significantly (p<0.05) upregulated protein spots in pair-wise comparison between different groups of rats were subjected to LC-MS/MS analysis for protein identification. The results showed that upregulation of anionic trypsin 1 and 2 in diabetic rats fed with ND compared to control rats fed with the same diet. The upregulation of these two proteins in diabetic rats acts as the defense mechanism against pancreatic tissue inflammation upon HFD intake. Moreover, upregulation of chymotrypsinogen B and transgelin-3 were detected in diabetic rats fed with HFD compared to those fed with ND, suggesting that these proteins may be induced by HFD intake, where upregulation of chymotrypsinogen B is a sign of pancreatic inflammation. Thus, HFD may influence specific pancreatic processes based on the observed protein changes.
- 25 December 2024
- Published by Persatuan Biologi Gunaan Malaysia in Malaysian Applied Biology
- Vol. 53 (6) , 49-57
Open AccessChanges of Pancreatic Protein Profile Upon High Fat Diet Intake In Diabetic Rat Model
The impact of a high-fat diet (HFD) on changes in pancreatic protein expression of the T2DM rat model was investigated. This is important as proteins are the functional components that regulate an organ’s activity. Adult male Sprague-Dawley rats were induced to diabetes using streptozotocin (STZ) and nicotinamide (NA). The diabetic rats and control rats were respectively fed with either a normal diet (ND) or a high-fat diet (HFD) that contained 39% fat for 6 consecutive weeks. The pancreases were harvested from the rats for proteomic analysis upon completion of the treatment period. Two-dimensional electrophoresis (2-DE) analysis was applied for protein separation and the significantly (p<0.05) upregulated protein spots in pair-wise comparison between different groups of rats were subjected to LC-MS/MS analysis for protein identification. The results showed that upregulation of anionic trypsin 1 and 2 in diabetic rats fed with ND compared to control rats fed with the same diet. The upregulation of these two proteins in diabetic rats acts as the defense mechanism against pancreatic tissue inflammation upon HFD intake. Moreover, upregulation of chymotrypsinogen B and transgelin-3 were detected in diabetic rats fed with HFD compared to those fed with ND, suggesting that these proteins may be induced by HFD intake, where upregulation of chymotrypsinogen B is a sign of pancreatic inflammation. Thus, HFD may influence specific pancreatic processes based on the observed protein changes.
- 21 February 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-17
Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions
Background Our previous study investigated the levels of soluble growth factors in the conditioned media of bone marrow-derived mesenchymal stem cells (BMSCs) pre-treated with thiazolidinedione solutions. The present study aimed to investigate the complex intracellular proteins extracted from BMSCs pre-treated with pioglitazone and/or rosiglitazone using proteomics. Methods The proliferative effect of the identified protein on MCF-7 cells that interacted non-adhesively with BMSCs pre-treated with pioglitazone and/or rosiglitazone was evaluated using cell culture inserts and conditioned media. The mRNA expression of proliferation and lipid accumulation markers was also evaluated in the interacted MCF-7 cells by reverse transcription-quantitative PCR. Finally, the correlation between the identified protein and fibroblast growth factor 4 (FGF-4) protein in the conditioned media of the pre-treated BMSCs was evaluated by ELISA. Results The present study identified vimentin as the specific protein among the complex intracellular proteins that likely plays a role in MCF-7 cell proliferation when the breast cancer cells interacted non-adhesively with BMSCs pre-treated with a combination of pioglitazone and rosiglitazone. The inhibition of this protein promoted the proliferation of MCF-7 cells when the breast cancer cells interacted with pre-treated BMSCs. Gene expression analysis indicated that pre-treatment of BMSCs with a combination of pioglitazone and rosiglitazone decreased the mRNA expression of Ki67 and proliferating cell nuclear antigen in MCF-7 cells. The pre-treatment did not induce mRNA expression of PPARγ, which is a sign of lipid accumulation. The level of vimentin protein was also associated with the FGF-4 protein expression level in the conditioned media of the pre-treated BMSCs. Bioinformatics analysis revealed that vimentin regulated the expression of FGF-4 through its interaction with SRY-box 2 and POU class 5 homeobox 1. Conclusions The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness.
- 21 February 2024
- Published by Springer Nature in Molecular Biology Reports
- Vol. 51 (1) , 1-17
Vimentin protein is a factor for decreasing breast cancer cell proliferation co-culture with human bone marrow-derived mesenchymal stem cells pre-treated with thiazolidinedione solutions
Background Our previous study investigated the levels of soluble growth factors in the conditioned media of bone marrow-derived mesenchymal stem cells (BMSCs) pre-treated with thiazolidinedione solutions. The present study aimed to investigate the complex intracellular proteins extracted from BMSCs pre-treated with pioglitazone and/or rosiglitazone using proteomics. Methods The proliferative effect of the identified protein on MCF-7 cells that interacted non-adhesively with BMSCs pre-treated with pioglitazone and/or rosiglitazone was evaluated using cell culture inserts and conditioned media. The mRNA expression of proliferation and lipid accumulation markers was also evaluated in the interacted MCF-7 cells by reverse transcription-quantitative PCR. Finally, the correlation between the identified protein and fibroblast growth factor 4 (FGF-4) protein in the conditioned media of the pre-treated BMSCs was evaluated by ELISA. Results The present study identified vimentin as the specific protein among the complex intracellular proteins that likely plays a role in MCF-7 cell proliferation when the breast cancer cells interacted non-adhesively with BMSCs pre-treated with a combination of pioglitazone and rosiglitazone. The inhibition of this protein promoted the proliferation of MCF-7 cells when the breast cancer cells interacted with pre-treated BMSCs. Gene expression analysis indicated that pre-treatment of BMSCs with a combination of pioglitazone and rosiglitazone decreased the mRNA expression of Ki67 and proliferating cell nuclear antigen in MCF-7 cells. The pre-treatment did not induce mRNA expression of PPARγ, which is a sign of lipid accumulation. The level of vimentin protein was also associated with the FGF-4 protein expression level in the conditioned media of the pre-treated BMSCs. Bioinformatics analysis revealed that vimentin regulated the expression of FGF-4 through its interaction with SRY-box 2 and POU class 5 homeobox 1. Conclusions The present study identified a novel intracellular protein that may represent the promising target in pre-treated BMSCs to decrease the proliferation of breast cancer MCF-7 cells for human health and wellness.
- Open Access
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 20 (1) , 102-113
Upregulation of Brain's Calcium Binding Proteins in Mitragynine Dependence: A Potential Cellular Mechanism to Addiction
Background: Mitragyna speciosa Korth or Kratom is widely used traditionally for its medicinal values. The major alkaloid content of kratom leaves is mitragynine, which binds to opioid receptors to give opioid-like effects. This study aimed to analyse the brain proteome of animals that displayed addictive behaviors.
- 1 January 2023
- Published by Ivyspring International Publisher in International Journal of Medical Sciences
- Vol. 20 (1) , 102-113
Open AccessUpregulation of Brain's Calcium Binding Proteins in Mitragynine Dependence: A Potential Cellular Mechanism to Addiction
Background: Mitragyna speciosa Korth or Kratom is widely used traditionally for its medicinal values. The major alkaloid content of kratom leaves is mitragynine, which binds to opioid receptors to give opioid-like effects. This study aimed to analyse the brain proteome of animals that displayed addictive behaviors.
- Open Access
- 28 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Pharmacology
- Vol. 11 (3) , 16-26
Controversial usages of kratom (Mitragyna speciosa): For good or for evil
Controversial usages of kratom (Mitragyna speciosa): For good or for evil
- 28 November 2022
- Published by Baishideng Publishing Group Inc. in World Journal of Pharmacology
- Vol. 11 (3) , 16-26
Open AccessControversial usages of kratom (Mitragyna speciosa): For good or for evil
Controversial usages of kratom (Mitragyna speciosa): For good or for evil
- 30 September 2022
- Published by Springer Nature
- p. 791-807
Urinary Profiling with Liquid Chromatography-Mass Spectrometry
- 30 September 2022
- Published by Springer Nature
- p. 791-807
Urinary Profiling with Liquid Chromatography-Mass Spectrometry
- 15 August 2022
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 70 (2) , 707-715
Development and validation of ELISA for screening of Kratom (Mitragyna speciosa) habitual users using urinary AZ122 biomarker
Kratom (Mitragyna speciosa Korth) has been used traditionally in Southeast Asia for its therapeutic properties. The major alkaloid of kratom, mitragynine, binds to opioid receptors to give opioid‐like effects that causes addiction. In our previous study, we have identified AZ122 as a unique biomarker in habitual or regular kratom users through analysis of their urinary protein profiles. We aimed to develop and validate a screening method by means of enzyme‐linked immunosorbent assay (ELISA) for detection of kratom habitual users. An ELISA approach was applied for the development of a screening method using urinary AZ122 as biomarker. Method validation was carried out using three quality control materials at different concentration of AZ122. The data was analyzed statistically using SPSS (Version 25). The ELISA was presented with Pearson correlation coefficient of 0.9993. The repeatability and reproducibility were presented at CV n = 88 regular kratom users and n = 88 healthy controls), the specificity and sensitivity of the assay were both 100%. The ELISA has been validated and can be potentially used as a reliable screening test for detection of kratom habitual users.
- 15 August 2022
- Published by Wiley in Biotechnology and Applied Biochemistry
- Vol. 70 (2) , 707-715
Development and validation of ELISA for screening of Kratom (Mitragyna speciosa) habitual users using urinary AZ122 biomarker
Kratom (Mitragyna speciosa Korth) has been used traditionally in Southeast Asia for its therapeutic properties. The major alkaloid of kratom, mitragynine, binds to opioid receptors to give opioid‐like effects that causes addiction. In our previous study, we have identified AZ122 as a unique biomarker in habitual or regular kratom users through analysis of their urinary protein profiles. We aimed to develop and validate a screening method by means of enzyme‐linked immunosorbent assay (ELISA) for detection of kratom habitual users. An ELISA approach was applied for the development of a screening method using urinary AZ122 as biomarker. Method validation was carried out using three quality control materials at different concentration of AZ122. The data was analyzed statistically using SPSS (Version 25). The ELISA was presented with Pearson correlation coefficient of 0.9993. The repeatability and reproducibility were presented at CV n = 88 regular kratom users and n = 88 healthy controls), the specificity and sensitivity of the assay were both 100%. The ELISA has been validated and can be potentially used as a reliable screening test for detection of kratom habitual users.
- 5 March 2022
- Published by Springer Nature
- p. 1-17
Urinary Profiling with Liquid Chromatography-Mass Spectrometry
- 5 March 2022
- Published by Springer Nature
- p. 1-17
Urinary Profiling with Liquid Chromatography-Mass Spectrometry
- 8 November 2021
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 40 (2) , 235-246
Characterization of urinary protein profile in regular kratom ( Mitragyna speciosa korth.) users in Malaysia
Mitragyna speciosa (Korth.) also known as kratom or ketum has been traditionally used for its diverse medicinal value in Southeast Asia. Despite of its therapeutic value, kratom’s safety profile remains deficiently elucidated. Our study aims to characterize the urinary protein profile of regular kratom users to determine its toxic effects on renal functioning. A total of 171 respondents (comprising of n = 88 regular kratom users, and n = 83 healthy controls) were recruited for this study. Urine specimens were collected and analyzed using SDS-PAGE, followed by LC/MS/MS analysis. Our results show albumin is the primary, and most abundant form of protein excreted in kratom user’s urine specimens (n = 60/64), indicating that kratom users are predisposed to proteinuria. Kratom users had an elevated urinary protein (with an intensity of 66.7 kDa band), and protein: creatinine ratio (PCR) concentrations relative to healthy controls. However, kratom user’s urinary creatinine concentration was found to be in the normal range as the healthy control group. While, kratom users who tested positive for illicit drug use had an elevated urinary albumin concentration. Our preliminary findings indicate that regular consumption of freshly brewed kratom solution over a protracted period (for an average of eleven years) seems to induce proteinuria, suggestive of an early stage of kidney injury. Hence, further studies are urgently needed to confirm our findings, and establish kratom’s renal impairing effects.
- 8 November 2021
- Published by Taylor & Francis in Journal of Addictive Diseases
- Vol. 40 (2) , 235-246
Characterization of urinary protein profile in regular kratom ( Mitragyna speciosa korth.) users in Malaysia
Mitragyna speciosa (Korth.) also known as kratom or ketum has been traditionally used for its diverse medicinal value in Southeast Asia. Despite of its therapeutic value, kratom’s safety profile remains deficiently elucidated. Our study aims to characterize the urinary protein profile of regular kratom users to determine its toxic effects on renal functioning. A total of 171 respondents (comprising of n = 88 regular kratom users, and n = 83 healthy controls) were recruited for this study. Urine specimens were collected and analyzed using SDS-PAGE, followed by LC/MS/MS analysis. Our results show albumin is the primary, and most abundant form of protein excreted in kratom user’s urine specimens (n = 60/64), indicating that kratom users are predisposed to proteinuria. Kratom users had an elevated urinary protein (with an intensity of 66.7 kDa band), and protein: creatinine ratio (PCR) concentrations relative to healthy controls. However, kratom user’s urinary creatinine concentration was found to be in the normal range as the healthy control group. While, kratom users who tested positive for illicit drug use had an elevated urinary albumin concentration. Our preliminary findings indicate that regular consumption of freshly brewed kratom solution over a protracted period (for an average of eleven years) seems to induce proteinuria, suggestive of an early stage of kidney injury. Hence, further studies are urgently needed to confirm our findings, and establish kratom’s renal impairing effects.